Alan Roemer

The Trout Group LLC operates as an investor relations and strategic advisory firm servicing the life science industry. It offers investor relations strategy, targeting and outreach, market intelligence, investor relation event planning and execution, investor relations materials, and corporate communications services. The company was founded by Jonathan B. Fassberg in 2004 and is headquartered in New York, NY.

Sio Gene Therapies, Inc. is a clinical-stage biopharmaceutical company, which engages in the acquisition, development, and commercialization of gene therapies for neurological diseases. The company was founded on October 31, 2014 and is headquartered in New York, NY.

Part of Sio Gene Therapies, Inc., Axovant Sciences, Inc. is a company that manufactures and distributes pharmaceutical products. The company is based in New York, NY.

Envisagenics, Inc. engages in developing of artificial intelligence platform for discovering drugs. The company was founded by Maria Luisa Pineda and Martin Akerman and is headquartered in New York, NY.

Roivant Sciences, Inc. operates as a pharmaceutical firm. It develops and markets drugs. The firm specializes in uterine fibroids, endometriosis, prostate cancer, diabetes, and pulmonary arterial hypertension. The company was founded by Vivek Ramaswamy in 2014 and is headquartered in New York, NY.

Utility Therapeutics Ltd. is a British company that has exclusive US commercial rights to two European-approved antibiotics, mecillinam and an oral prodrug of mecillinam, for the treatment of urinary tract infections (UTI). The private company is based in Altrincham, UK and was founded in 2018 by Rasmus Toft-Kehler, Morten Otto Alexander Sommer, Peter Aksel Villadsen. Mecillinam is being developed as a first-line therapy for complicated UTI in the hospital setting, while the oral prodrug is being developed for uncomplicated UTI. The company has received the FDA's Qualified Infectious Disease Product (QIDP) designation for the treatment of UTI. Utility Therapeutics is committed to developing antibiotics that meet urgent treatment needs for multi-drug resistant infections.

Bit Bio Ltd. engages in research and experimental development on natural sciences and engineering. Its products are human-induced skeletal myocytes and glutamatergic neurons. The company was founded by Mark Kotter in 2016 and is headquartered in Cambridge, the United Kingdom.